Beyond Air (NASDAQ: XAIR) — Company Overview, News & Financial Data
Beyond Air develops innovative medical devices targeting lung diseases, focusing on Nitric Oxide therapies.
Beyond Air
Beyond Air (NASDAQ:XAIR) is focused on developing innovative medical devices and therapies aimed at transforming treatment options for patients with lung diseases and severe infections. The company has a diverse portfolio of projects, including advanced systems for Nitric Oxide delivery that target a range of medical conditions, from chronic lung infections to certain types of cancer. Beyond Air's objectives are centered around harnessing the therapeutic potential of Nitric Oxide to offer safer, more effective treatments, and improving patient outcomes across the globe. Aiming to push the boundaries of medical science, Beyond Air is committed to research, development, and commercialization of cutting-edge medical technologies.
Snapshot
Operations
Products and/or services of Beyond Air
- LungFit PH system for generating high concentration nitric oxide (NO) from ambient air for treating various respiratory infections.
- LungFit GO, a portable system for NO therapy in outpatient settings.
- LungFit BRO, designed for the treatment of bronchiolitis in hospitalized infants, using nitric oxide.
- Pipeline development for treating chronic obstructive pulmonary disease (COPD) with nitric oxide therapies.
- Research on high-dose nitric oxide therapy for the treatment of COVID-19.
- Advancements in using nitric oxide for treating nontuberculous mycobacterial (NTM) lung disease.
Beyond Air executive team
- Mr. Steven Adam LisiCEO & Chairman of the Board
- Mr. Michael A. GaulChief Operating Officer
- Mr. Amir AvnielChief Executive Officer of NeuroNOS
- Mr. Daniel J. Moorhead CPAChief Financial Officer
- Mr. Denton DrewellPrincipal Accounting Officer & Controller
- Dr. Andrew R. Colin M.D.Senior Medical Director Global Clinical Leadership & Member of Scientific Advisory Board
- Dr. John Jett Ph.D.Head of Research & Clinical Development
- Mr. Robert Scott GoodmanInterim Chief Commercial Officer & Director
- Mr. Adam T. NewmanCorporate Secretary